PhD Mervi Ristola Succeeded in the Tough Competition for Academy of Finland Postdoctoral Funding
BioMediTech researcher, PhD Mervi Ristola received postdoctoral funding from Academy of Finland to study demyelinating disesases, which damage the myelin sheath protecting nerve fibres in the brain. Demyelinating disorders, such as multiple sclerosis, are the most common disabling neurological diseases of young adults worldwide.
The competition for funding was exceptionally tough this year with only nine percent success rate. The Academy of Finland’s Research Council for Health decided to fund 14 new research posts as Postdoctoral Researcher. The three-year funding periods will start in September 2016.
Read more on Academy Finland website
BioMediTech Moves ongoing on Kauppi Campus
During the summer, BioMediTech offices and laboratories on Kauppi campus are moving to the new Arvo building. BioMediTech institute together with School of Medicine and School of Health Sciences at UTA will be able to use the space of over 23,000 m2 for different teaching and research purposes.
By the beginning of autumn term, Arvo will house approximately 600 employees and 1,200 students. The modern facilities and the top-level equipment provide good opportunities for high-level teaching and the work of top-level researchers. Arvo is located in Lääkärinkatu 1, Tampere.
BioMediTech is Developing a New Treatment for Corneal Damage
A novel stem cell-based treatment method for serious corneal damage is being developed at BioMediTech (BMT), the joint institute of the University of Tampere and Tampere University of Technology. A new project is about to start investigating how this innovation could be made available to patients and the doctors who treat them.
The project is being carried out by Associate Professor Heli Skottman and her research team together with BMT’s business development team in cooperation with international experts.
The ultimate goal of the project is to find ways of treating those patients in particular who have a limbal stem cell deficiency in both eyes. Currently, no treatment is available for these patients.
The EUR 750,000 project is funded by the University of Tampere together with TEKES – the Finnish Funding Agency for Innovation, which is providing the two-and-a-half year project with EUR 526,000 from the “New knowledge and business from research ideas” research fund.
Read more on UTA Research & Study News
Funding for Developing International Operations
The council of Tampere region has given BioMediTech 45,960 € for enhancing BioMediTech’s international operations. The council of Tampere region prepares to fund the project with 174,300 in total by June, 2018, but the decision made now was for the year 2016.
The project aims at utilising the cooperation with the BioVille business incubator in Belgium to better reach the markets and partners in Central Europe for innovations coming from top-quality research.
More information from:
Juho Väisänen, Programme Manager juho.vaisanen (at) biomeditech.fi
Annual Report 2015 available
BioMediTech Annual Report 2015 has been published online. The Annual Report is available both in Finnish and in English. This year, it will only be published in electronic form.